Shen Ying, Chao Bao-Hua, Cao Lei, Tu Wen-Jun, Wang Long-De
Department of Traditional Chinese Medicine, Xuanwu Hospital Capital Medical University, Beijing, China.
The General Office of Stroke Prevention Project Committee, National Health Commission of the People's Republic of China, No. 118, Guang'anmen Inner Street, Beijing, 100053, People's Republic of China.
Transl Stroke Res. 2020 Jun;11(3):377-386. doi: 10.1007/s12975-019-00727-6. Epub 2019 Sep 8.
The aim of this study was to assess the association between admission to stroke centers for acute ischemic stroke and complications and mortality during hospitalization in a Chinese population by means of an observational study using data from the China Stroke Center Data-Sharing Platform. We compared in-hospital complications and mortality for patients admitted with acute ischemic stroke (N = 13,236) between November 1, 2018 and December 31, 2018 at stroke center (SH) and non-stroke center (CH) hospitals using distance to hospitals as an instrumental variable to adjust for potential prehospital selection bias. The results showed that complication rates during hospitalization among ischemic stroke patients who received thrombolytic therapy (n = 11,203) were lower in the SH group than in the CH group: 11.1% vs 15.7% (absolute difference, - 5.11% [95% CI, - 6.05 to - 3.99%], odds ratio [OR] 0.85 [95% CI, 0.74 to 0.92]). The incidence of intracranial hemorrhage was reduced from 4.2 to 3.2%: SH group vs CH group, 3.2% vs 4.2% (absolute difference, - 1.24% [95% CI, - 1.65 to - 0.82%], OR 0.83 [95% CI, 0.69 to 0.0.98]). Furthermore, the total mortality rate in the SH group was also lower than in the CH group: SH group vs CH group, 2.2% vs 3.0% (absolute difference, - 0.92% [95% CI, - 1.48 to - 0.53%], OR 0.85 [95% CI, 0.73 to 0.96]). The data showed that admission to SH hospitals was associated with a lower risk of treatment complications and death for patients with an acute ischemic stroke receiving thrombolytic therapy.
本研究旨在通过一项观察性研究,利用中国卒中中心数据共享平台的数据,评估中国人群中急性缺血性卒中患者入住卒中中心与住院期间并发症及死亡率之间的关联。我们比较了2018年11月1日至2018年12月31日期间,以到医院的距离作为工具变量来调整潜在的院前选择偏倚,在卒中中心(SH)医院和非卒中中心(CH)医院收治的急性缺血性卒中患者(N = 13236)的院内并发症及死亡率。结果显示,接受溶栓治疗的缺血性卒中患者(n = 11203)中,SH组的住院并发症发生率低于CH组:分别为11.1%和15.7%(绝对差异为 - 5.11% [95%CI,- 6.05至 - 3.99%],优势比[OR]为0.85 [95%CI,0.74至0.92])。颅内出血发生率从4.2%降至3.2%:SH组为3.2%,CH组为4.2%(绝对差异为 - 1.24% [95%CI,- 1.65至 - 0.82%],OR为0.83 [95%CI,0.69至0.98])。此外,SH组的总死亡率也低于CH组:SH组为2.2%,CH组为3.0%(绝对差异为 - 0.92% [95%CI,- 1.48至 - 0.53%],OR为0.85 [95%CI,0.73至0.96])。数据表明,对于接受溶栓治疗的急性缺血性卒中患者,入住SH医院与较低的治疗并发症风险及死亡风险相关。